Active	Status	Sponsor type	Region	Phase	Filter
1 Active 17 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dalcetrapib (JTT-705) / DalCor
dal-GenE-2, NCT05918861: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Recruiting	3	2000	Canada, US	Dalcetrapib, Cholesterol Ester Transfer Protein Inhibitor, Placebo, Dalcetrapib matching placebo tablets	DalCor Pharmaceuticals, The Montreal Health Innovations Coordinating Center (MHICC)	Acute Coronary Syndrome	08/27	08/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
dalcetrapib (JTT-705) / DalCor
dal-GenE-2, NCT05918861: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS	Recruiting	3	2000	Canada, US	Dalcetrapib, Cholesterol Ester Transfer Protein Inhibitor, Placebo, Dalcetrapib matching placebo tablets	DalCor Pharmaceuticals, The Montreal Health Innovations Coordinating Center (MHICC)	Acute Coronary Syndrome	08/27	08/27